Bcl-2 proteins are over-expressed in many tumors and are critically important for cell survival. Their anti-apoptotic activities are determined by intracellular localization and posttranslational modifications (such as phosphorylation). Here, we showed that WAVE1, a member of the Wiskott-Aldrich syndrome protein family, was over-expressed in blood cancer cell lines, and functioned as a negative regulator of apoptosis. Further enhanced expression of WAVE1 by gene transfection rendered leukemia cells more resistant to anti-cancer druginduced apoptosis; whereas suppression of WAVE1 expression by RNA interference restored leukemia cells' sensitivity to antidrug-induced apoptosis. WAVE1 was found to be associated with mitochondrial Bcl-2, and its depletion led to mitochondrial release of Bcl-2, and phosphorylation of ASK1/JNK and Bcl-2. Furthermore, depletion of WAVE1 expression increased anticancer drug-induced production of reactive oxygen species in leukemia cells. Taken together, these results suggest WAVE1 as a novel regulator of apoptosis, and potential drug target for therapeutic intervention of leukemia.
Introduction
Apoptosis has now been widely accepted as a prominent tumorsuppression mechanism. 1 It is mediated by two central pathways: an extrinsic pathway triggered by cell death receptors (such as Fas), and an intrinsic pathway triggered by the mitochondrial release of cytochrome c and its subsequent complex formation with Apaf-1, ATP, and caspase-9. 1 A pivotal event in the mitochondrial pathway mitochondrial outer membrane permeabilization, which is mainly regulated by Bcl-2 family members [anti-apoptotic (for example Bcl-2 and Bcl-XL) or pro-apoptotic (for example Bax, Bid, Bad, and Bak)]. 2 Bcl-2 is an anti-apoptotic member of the Bcl-2 family, and has an important function in the regulation of apoptosis, tumorigenesis, and cellular responses to anti-cancer therapy. 2 Overexpression of Bcl-2 inhibits stress-induced cell death and promotes hemopoietic cell survival. 2 Bcl-2 is localized to the mitochondrial membrane as well as endoplasmic reticulum (ER) and nuclear membranes. The anti-apoptotic activity of Bcl-2 is regulated by its intracellular localization and post-translational modification such as phosphorylation. [3] [4] [5] [6] However, the intricate molecular mechanisms underlying Bcl-2 subcellular localization and intermolecular interactions are not fully understood.
The family of Wiskott-Aldrich syndrome proteins including WAVE1, WAVE2, WAVE3, WASP, N-WASP, are involved in transduction of signals from receptors on the cell surface to the actin cytoskeleton. 7 As an essential process for cell morphologic changes and motility, cytoskeleton reorganization is also an important regulator of apoptotic cell death. 8 WAVE1 is expressed most abundantly in murine brain tissue, and at extremely low levels in other tissues including heart, liver, lung, kidney, pancreas, and peripheral blood. 9 Although essential for the normal central nervous system development and mammalian fertilization, 10, 11 WAVE1 can also interact with a number of mitochondrial proteins (for example glucokinase and PKA), thereby coordinating death and glycolysis. 12 In addition, WAVE1 also interacts with pancortin-2 in a mitochondria-associated protein complex, and mediates ischemic neuronal death. 13, 14 These findings support a general role for WAVE1 in the regulation of mitochondria function.
Leukemia is a malignant disease of the bone marrow and blood, and is the most common form of cancers in children. We have recently found that WAVE1 was involved in multidrug resistance and oxidative stress of human leukemia cells, 15, 16 but its pathogenic role in leukemia were not fully understood. Here, we showed that WAVE1 was over-expressed in both human blood cancer cells lines and primary bone marrow mononuclear cells of patients with childhood leukemia. Elevation of WAVE1 expression by gene transfection rendered leukemia cells resistant to apoptosis; whereas suppression of WAVE1 expression by RNA interference increased the sensitivity of leukemia cells to anti-cancer drugs. Furthermore, our experimental data suggested a role for WAVE1 in the regulation of apoptosis partly through controlling Bcl-2 localization and phosphorylation, supporting a potential pathogenic role for the WAVE1-Bcl-2 axis in leukemia.
Materials and methods

Materials and plasmids
The antibodies to WAVE1, WAVE2, and monoamine oxidase B (MAO-B) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The antibodies to GAPDH, and Tubulin were obtained from Sigma (St Louis, MO, USA). The antibodies to Bcl-2, Phospho-Bcl-2 (Ser70), Bcl-XL, Bad, Bid, H3, COXIV, Phospho-SAPK/JNK (Thr183/Tyr185), Phospho-p38 (Thr180/ Tyr182), Phospho-ASK1 (Thr845), Phospho-Rac1/cdc42 (Ser71), GFP-Tag and Myc-Tag were obtained from Cell Signaling Technology (Danvers, MA, USA). The antibody to Caspase 12 was obtained from Millipore (Lake Placid, NY, USA). The antibody to mitochondria HSP70 (mHSP70) was obtained from Abcam (Cambridge, MA, USA). The antibody to PDI and Calnexin was obtained from NOVUS (Littleton, CO, USA 
Gene transfection and RNAi
Expression vector transfection or co-transfection with WAVE1 shRNA was obtained using FuGENE HD Transfection Reagent (Roche Applied Science, Stockholm, Sweden) or Lipofectamine 2000 reagent (Life Technologies) according to the manufacturer's instructions. Human WAVE1-siRNA or control-siRNA was transfected into cells using X-tremeGENE siRNA reagent (Roche Applied Science) according to the manufacturer's instructions.
Cell viability assay
After drug treatment, cell viability was evaluated with Cell Counting Kit-8 (CCK8) (Dojindo, Tokyo, Japan) according to the manufacturer's instructions.
Assessment of apoptosis
After drug treatment, cytocentrifuge preparations were stained with Hoechst 33258 and viewed by fluorescence microscopy to evaluate the extent of apoptosis as described earlier. 19 For each condition, five randomly selected fields, encompassing 4500 cells, were scored. To confirm the results of morphologic analysis, flow cytometric analysis of annexin V/PI-stained cells was performed. In all studies, the results of morphologic assessment and annexin V/PI staining yielded highly concordant results.
Measurement of intracellular ROS and calcium
ROS was assessed with cell permeable dye CM-H2DCFDA (Molecular Probes, Carlsbad, CA, USA), cytosolic-free Ca 2 þ using CaGreen-1 (Molecular Probes) and mitochondrial Ca 2 þ using Rhod-2 (Molecular Probes) according to the manufacturer's instructions. Labeled cells were washed twice with PBS or calcium-free Krebs-Henseleit buffer (Sigma). Analysis was performed using flow cytometry.
Preparation of cellular extracts
At the designated time after the treatment, cells were harvested. Mitochondrial and cytoplasmic purification was performed with Optiprep Mitochondria Isolation Kit (Pierce, Rockford, IL, USA) according to the manufacturer's instructions. Crude ER purification was performed with Endoplasmic Reticulum Isolation Kit (Sigma) according to the manufacturer's instructions.
Patients and cell separation
We obtained diagnostic childhood acute lymphoblastic leukemia (ALL) and acute nonlymphocytic leukemia (ANLL) bone marrow samples after informed consent and with the approval of research ethics committee at Central South University. The diagnoses of ALL and ANLL were based on morphology and flow cytometric analysis of immunophenotype. BMMCs or PBMCs were isolated by Ficoll density gradient centrifugation.
Western blotting analysis
Proteins in whole-cell lysate or subcellular fractions were resolved on 10% SDS-PAGE gel, and transferred to a polyvinylidene fluoride membrane. After blocking the membrane at room temperature for 3 h, the membrane was incubated overnight at 4 1C with various primary antibodies. After incubation with peroxidase-conjugated secondary antibodies for 1 h at 25 1C, the signals were visualized using enhanced chemiluminescence (Pierce).
20,21
Immunoprecipitation analysis Cells or cell fractionation were lysed at 4 1C in ice-cold lysis buffer (50 mM Tris-HCl, pH 7.4, containing 150 mM NaCl, 1% NP-40, 0.5% Na-deoxycholate, 0.1% SDS, protease inhibitors cocktail), and cell lysates were cleared by a brief centrifugation (12 000 g, 10 min). Concentrations of proteins in the supernatant were determined by the BCA assay. Before immunoprecipitation, samples containing equal amount of proteins were pre-cleared with Protein A or protein G agarose/ sepharose (Amersham Biosciences, Piscataway, NJ, USA) (4 1C, 3 h), and subsequently incubated with various irrelevant IgG or specific antibodies (5 mg/ml) in the presence of protein A or G agarose/sepharose beads for 2 h or overnight at 4 1C with gently shaking. 20, 21 After incubation, agarose/sepharose beads were washed extensively with PBS, and proteins eluted by boiling in 2 Â SDS sample buffer before SDS-PAGE electrophoresis.
Caspase activity assay
Caspase-3 activity was assayed using the Caspase-3 Colorimetric Assay Kit (Calbiochem, Berlin, Germany) according to the manufacturer's instructions.
Immunocytochemical analysis the mitochondrial localization of WAVE1
Cells were fixed in 4% formaldehyde for 30 min at room temperature before cell permeabilization with 0.1% Triton X-100 (4 1C, 10 min). Cells were saturated with PBS containing WAVE1 regulates Bcl-22% BSA for 1 h at room temperature and processed for immunofluorescence with anti-WAVE1 antibody followed by Alexa Fluor 488-conjugated Ig and MitoTracker (Molecular Probes). Between all incubation steps, cells were washed three times for 3 min with PBS containing 0.2% BSA. 22, 23 Fluorescence signals were analyzed using a confocal fluorescence microscope (Olympus, Tokyo, Japan).
Statistical analysis
Data are expressed as the mean±s.e.m. Significance of differences between groups was determined by two-tailed Student's t-test or Fisher's LSD test. Po0.05 was considered significant.
Results
WAVE1 is over-expressed in human leukemia cell lines and renders cells resistant to chemotherapeutics-induced apoptosis
We first determined the levels of WAVE1 expression in five leukemia cell lines (HL60, K562, HL-60/MX2, Jurkat, and Raji) by western blotting analysis. Levels of WAVE1 expression were high in all five human leukemia cancer cell lines ( Figure 1a ). In contrast, the constitutive expression levels of WAVE1, but not WAVE2, were noticeably lower in nonblood cancer cell-lines, including human lung A549 cancer cells, Hela cervical cancer cells, MG-63 osteosarcoma cells, CNE2 nasopharyngeal carcinoma cells, human umbilical vein endothelial cell, QSG7701 hepatocarcinoma cells, and WI-38 lung fibroblastoma cells (Figure 1a) , suggesting that a different role of WAVE1 in leukemia tumorigenesis.
To evaluate the clinical relevance, we determined the relative WAVE1 protein expression levels in BMMCs obtained from 37 patients with acute lymphocytic leukemia (18 patients in primary phase, 5 in relapse phase, and 14 in complete remission phase) and 12 patients with ANLL (6 patients in primary phase, 3 in relapse phase, and 3 in complete remission phase). Higher levels of WAVE1 expression were found in BMMCs derived from patients with primary and relapse leukemia (Figure 1b) . In contrast, consistent with the absence of WAVE1 expression in normal PBMCs, WAVE1 was not detectable in BMMCs derived from normal healthy subjects, or patients with complete remission (Figure 1b ), suggesting that WAVE1 may reflect stages of hemocyte differentiation and maturation.
To explore the potential role for WAVE1 in the regulation of apoptotic cell death of leukemia cells, a target-specific siRNA duplex against WAVE1 was transferred into HL-60 and Jurkat leukemia cells. Transfection of WAVE1-siRNA led to a significant decrease in WAVE1 protein in these cells (Figure 1c) . Depletion of WAVE1 expression in these cells rendered them significantly more sensitive to VCR, arsenic trioxide (AS2O3), and ADM-induced apoptotic cell death, which were associated with high levels of caspase-3 activities (Figure 1c) .
To further characterize the role of WAVE1 in leukemia after chemotherapy, we transfected HL-60 leukemia cells with full-length human WAVE1 and WAVE2 cDNA. These WAVE1-overexpressing cells became resistant to apoptosis induced by VCR, ADM, and AS2O3 (Figure 1d) , suggesting a potential anti-apoptotic role for WAVE1 in leukemia cells. In contrast, overexpression of WAVE2 did not increase Relative expression levels of WAVE1 in childhood leukemia. Total protein was extracted from normal or patients' BMMCs, and equal amounts of proteins (30 mg) were loaded, and WAVE1 level was determined by the relative optical intensity (in arbitrary units, AU) of the immunoreactive bands on western blots. Each dot represents relative WAVE1 level in each individual sample. ALL, acute lymphoblastic leukemia; ANLL, acute nonlymphocytic leukemia; P, primary; CR, complete remission; R, relapse. *Po0.05 versus normal. #Po0.05 versus CR. (c) WAVE1 knockdown increased the sensitivity of leukemia cells to anti-cancer drug-induced apoptosis. Knockdown WAVE1 by siRNA in leukemia cells as indicated and then treated with VCR (1 mg/ml), ADM (1 mg/ml), and AS2O3 (5 mM). Cell apoptosis was examined at 24 and 48 h, and caspase-3 activity was examined at 24 h (n ¼ 3). UT, untreated group. *Po0.05 versus control-siRNA group. (d) WAVE1 overexpression rendered HL-60 leukemia cells resistant to anti-cancer drug-induced apoptosis. HL-60 cells transfected with WAVE1, WAVE2, and pEFBOS vector plasmid and then treat with VCR (1 mg/ml), ADM (1 mg/ml), and AS2O3 (5 mM). Cell apoptosis and caspase 3 activity was examined at 24 h (n ¼ 3). UT, untreated group. *Po0.05 versus empty vector group. (e) Knockdown of Bcl-2 by shRNA in WAVE1 overexpressing cells restored sensitivity to anti-cancer drug-induced apoptosis. HL-60 cells transfected with various plasmid were stimulated with VCR (1 mg/ml), ADM (1 mg/ml), and AS2O3 (5 mM). At 24 h after treatment, cell apoptosis was assayed (n ¼ 3, * , # Po0.05).
WAVE1 regulates Bcl-2 R Kang et al the resistance to anti-cancer drugs by apoptosis analysis or caspase-3 activity assay (Figure 1d ), supporting a specific role for WAVE1 in the pathogenesis of leukemia. In contrast, knockdown of Bcl-2 in WAVE1 overexpressing cells partially restored their sensitivity to anti-cancer drug-induced apoptosis, suggesting that WAVE1-mediated anti-apoptotic effects are partly Bcl-2 dependent (Figure 1e ).
WAVE1 regulates ROS production and Ca 2 þ homeostasis in leukemia cell apoptosis Many cellular processes including apoptosis are regulated by the ROS and calcium signal pathway. 2, 24 To gain insight into the intricate molecular mechanism by which WAVE1 regulates apoptosis in leukemia cells, we first investigated the effect of WAVE1 on intracellular ROS and Ca 2 þ homeostasis in apoptosis. Consistent with earlier study, 25 ADM increased ROS production, but not calcium. In contrast, thapsigargin (an inhibitor of sarco/ER Ca 2 þ ATPase involved in calcium sequestration by the ER) and H 2 O 2 (an agonist that induces the opening of the InsP3 receptors) increased ROS production, as well as cytosolic-free/mitochondrial Ca 2 þ . Notably, suppression of WAVE1 expression by siRNA increased these drug-induced ROS production and cytosolic-free/mitochondria Ca 2 þ (Figure 2a ), suggesting a potential role for WAVE1 in the regulation of ROS production and calcium homeostasis in leukemia. Moreover, addition of p-trifluoromethoxy carbonyl cyanide phenyl hydrazone (FCCP), a protonophore that leads to collapse of the mitochondrial membrane potential, 26 decreased the load of mitochondria Ca 2 þ in WAVE1 siRNA cells after thapsigargin and H 2 O 2 treatment (Figure 2b) . Furthermore, overexpression of WAVE1 rendered cells resistant to thapsigargin-induced ROS production, and elevation of cytosolic or mitochondrial Ca 2 þ levels ( Figure 2c ). In contrast, knockdown of Bcl-2 in WAVE1 overexpressing cells partially restored thapsigargin-induced production of ROS production, and elevation of cytosolic-free or mitochondrial Ca 2 þ levels (Figure 2c ), suggesting that WAVE1-mediated effects are partly Bcl-2 dependent.
WAVE1 regulates intracellular localization of Bcl-2 in leukemia cell
Similar to the mitochondrial localization of WAVE1 in neuronal cells, 14 WAVE1 was localized to the mitochondrial as well as cytosol and nuclear in leukemia cells (for example Jurkat and HL-60) by image and/or western blotting analysis (Figure 3a and b). Its mitochondrial localization provided a basis for its molecular interaction with divergent mitochondrial proteins, such as Bcl-2 and Bcl-XL. 3, [27] [28] [29] To further investigate the role of WAVE1 in leukemia, we determined the effects of WAVE1 depletion on mitochondrial localization of anti-apoptotic proteins Bcl-2. We found that WAVE1 knockdown decreased mitochondrial levels of (Mit)-Bcl-2, but increased cytosol levels of Bcl-2 in Jurkat cells (Figure 3c ). In contrast, WAVE1 overexpression significantly increased mitochondrial levels of Mit-Bcl-2 in Jurkat cells. However, WAVE1 did not influence Bcl-XL and Bad localization (Figure 3c ), indicating a specific role for WAVE1 in the regulation of Bcl-2 intracellular localization in leukemia cells.
WAVE1 binds Bcl-2 in mitochondria in leukemia cell
A recent study suggests that WAVE1 interacts with Bcl-XL in mitochondria in neuronal cells. 13 In a sharp contrast, CoIP assay revealed an association between WAVE1 and Bcl-2 (but not Bcl-XL, Bad and Bid) in Jurkat cells co-transfected with WAVE1-myc and Bcl-2-GFP cDNA (Figure 4a ). To confirm this interaction, we performed CoIP experiment using WAVE1 and Bcl-2 antibodies in Jurkat cells. Among many proteins tested, only Bcl-2 was found to be associated with WAVE1 in leukemia cells (Figure 4b ). To determine the functional localization for WAVE1/Bcl-2 interaction, plasmids encoding a mitochondriarestricted Bcl-2 (Mit-Bcl-2 containing a mitochondrial insertion sequence of MAO-B), or ER-restricted Bcl-2 (ER-Bcl-2 containing a ER-specific sequence of cytochrome b5) 6 were transfected into Jurkat cells. Fractionation experiments revealed that Bcl-2 was detected only in the mitochondrial fraction of the Mit-Bcl-2-expressing Jurkat cells, but in the ER fraction of ER-Bcl-2-expressing cells (Figure 4c ). CoIP assay indicated an 
WAVE1 regulates Bcl-2-mediated ROS production in leukemia cell
Bcl-2 is required to balance mitochondria ROS production and subsequent release of pro-death molecules. [3] [4] [5] [6] To determine the influence of WAVE1 on Bcl-2 function, we measured the ROS production and caspase-3 activity in cells transfected with various Bcl-2-expression or WAVE1-inhibition plasmid constructs. Transfection with wild-type Bcl-2 and Mit-Bcl-2, but not ER Bcl-2-GFP decreased ADM-induced ROS production, caspase-3 activity, and cell death (Figure 5a ), suggesting that Mit-Bcl-2 was important for mitochondria ROS production. Consistently, transfection of WAVE1-depleted (shRNA) cells with Mit-Bcl-2-GFP, but not the wild-type Bcl-2, also blocked ADM-induced ROS production and apoptosis (Figure 5a ). Furthermore, WAVE1 depletion impaired mitochondrial localization of wild-type Bcl-2-GFP, but not Mit-Bcl-2-GFP (Figure 5b) . The Mit-Bcl-2-GFP is constructed in human Bcl-2 gene by linking a mitochondrial targeting domain from MAO-B protein. Similarly, the mitochondrial localization of MAO-B was not influenced by WAVE1 knockdown in Jurkat cells (Figure 5c ), suggesting that WAVE1 regulated native Bcl-2 mitochondrial localization, rather than the restricted-mitochondrial targeting domain of MAO-B protein.
WAVE1 regulates Bcl-2-mediated Ca 2 þ homeostasis in leukemia cell ER-targeted Bcl-2 protects cell following most stress such as staurosporine, brefeldin A/cycloheximide, tunicamycin, thapsigargin, and ceramide. 2 Overexpression of ER-Bcl-2 decreased thapsigargininduced cytolic-free Ca 2 þ and mitochondria Ca 2 þ load, ROS generation, and caspase-12 and -3 activity in control shRNA Jurkat cell ( Figure 6 ). In contrast, overexpression of Mit-Bcl-2 did not inhibit ER-stress-induced ER Ca 2 þ release and mitochondria Ca 2 þ load in control shRNA Jurkat cell, indicated that the WAVE1 regulates Bcl-2 R Kang et al function of Bcl-2 was dependent on its subcellular localizations. Interestingly, WAVE1 deletion led to Bcl-2 translocation from mitochondria to ER in leukemia cells (Figure 7a ). The observations that WAVE1 knockdown increased thapsigargin-induced cytosolic-free/mitochondria Ca 2 þ level and cell death ( Figure 6 ), and that transfection with wild-type Bcl-2 in WAVE1 shRNA cells did not block thapsigargin-induced cytolic-free/mitochondria Ca 2 þ production and apoptosis ( Figure 6 ), suggest that WAVE1 may not only regulate Bcl-2 subcellular localization, but also its intracellular functions.
WAVE1 regulates Bcl-2 phosphorylation in an ASK1/JNK-dependent pathway
As phosphorylation of Bcl-2 is implicated in regulating Bcl-2 function, 30, 31 we further studied the role of WAVE1 in the regulation of Bcl-2 phosphorylation. Consistent with earlier studies, 30, 31 phosphorylated Bcl-2 was located in the ER, but not mitochondria (Figure 7a ). However, WAVE1 knockdown increased the phosphorylation of ER-bcl-2 (Figure 7a ). Consistently, Jurkat cells expressing a nonphosphorylatable Bcl-2AAA (T69A, S70A, S87A) mutant were found to be more resistant to thapsigargin-induced cell death (Figure 7b ). 30 Transfection with Bcl-2 AAA but not Bcl-2 WT in WAVE1 knockdown Jurkat cells decreased calcium production and cell death (Figure 7c and data not shown), suggesting that WAVE1 regulates Bcl-2 phosphorylation and function involving in ER Ca 2 þ homeostasis. The JNK pathway is responsible for phosphorylation of Bcl-2 in response to microtubule-damaging agents and calcium-dependent death stimuli. 18, 30, 31 Depletion of WAVE1 expression led to an increase in thapsigargin-induced phosphorylation of JNK1/2, but not p38 (Figure 7d) . Furthermore, WAVE1 depletion led to an increase in the phosphorylation of ASK1 (apoptosis signal-regulating kinase 1), but not small GTPases RAC1 (Ras-related C3 botulinum toxin substrate 1) (Figure 7d ). Pretreatment with JNK and ASK1 kinase, but not p38 and CDC42 kinase, promoted thapsigargin-induced Bcl-2 phosphorylation (Figure 7f ) and cell death (Figure 7e ), especially in control shRNA-transfected Jurkat cells (Figure 7e ). In contrast, JNK inhibitor SP600125, but not p38 inhibitor SB203580 decreased thapsigargin-induced Bcl-2 phosphorylation (Figure 7f ) and cell death (Figure 7e) . Collectively, these data indicate that WAVE1 regulates Bcl-2 phosphorylation in an ASK1/JNKdependent pathway.
Discussion
Although WAVE1-mediated actin-dependent morphological processes in mammals have been well known since 1996, 7, 32 its expression and function under pathological conditions is poorly understood. In this study, we showed that WAVE1 was expressed abundantly in human blood cancer cell lines, and barely in nonblood tumor cell-lines. To establish its clinical relevance, we determined WAVE1 expression levels in BMMCs derived from patients with childhood leukemia. WAVE1 expression was not detectable in PBMCs of normal healthy subjects, but detected at high levels in BMMCs of patients with ALL or ANLL, Furthermore, its expression levels correlated with Figure 4 WAVE1 binds Bcl-2 in mitochondria in leukemia cell. (a) CoIP assay Jurkat cells were transfected with plasmids encoding Myc-tagged WAVE1 and GFP-tagged Bcl-2, Bcl-xl, Bad, and Bid. Cell lysates normalized for total protein content were analyzed directly or subjected to IP using anti-Myc or anti-GFP antibody and were analyzed by western blotting using anti-Myc or anti-GFP antibodies. (b) Endogenous WAVE1 bind Bcl-2. Jurkat cells were treated with or without ADM for 24 h, and lysates were prepared for IP with control IgG or anti-WAVE1, anti-Bcl-2, anti-Bcl-xl, anti-Bad, anti-Bid. The resulting immune complexes were analyzed by western blotting using antibodies recognizing WAVE1, Bcl-2, Bcl-xl, Bad, or Bid. (c) Jurkat cells were transfected with plasmids encoding GFP-tagged Bcl-2, mitochondria-restricted Bcl-2 (Mit-Bcl-2), ER-restricted Bcl-2 (ER-Bcl-2). Cells were fractionated into mitochondrial (Mit), and nuclear (ER) and were analyzed by western blotting. PDI and mHSP70 were used as fraction isolation quality control. (d) CoIP assay Jurkat cells were transfected with plasmids encoding Myc-tagged WAVE1 and GFP-tagged Bcl-2, mitochondria-restricted Bcl-2 (Mit-Bcl-2), and ER-restricted Bcl-2 (ER-Bcl-2). Cell lysates normalized for total protein content were analyzed directly or subjected to IP using anti-Myc or anti-GFP antibody and were analyzed by western blotting using anti-Myc or anti-GFP antibodies. (e) Endogenous WAVE1 bind mitochondria Bcl-2. The cytosolic and mitochondria fractions were prepared and lysates were prepared for IP with anti-Bcl-2. The resulting immune complexes were analyzed by western blotting using antibodies recognizing WAVE1. The inputs were analyzed by western blotting using anti-mHSP70 and tubulin. WAVE1 regulates Bcl-2-mediated Ca 2 þ homeostasis in leukemia cell. Jurkat cells were co-transfected with expression plasmids (Bcl-2-GFP, Mit-Bcl-2-GFP, and ER-Bcl-2-GFP) and/or shRNA plasmids (WAVE1 shRNA and control shRNA), then stimulated with thapsigargin (100 nM) for 24 h, and assayed cell death, ER Ca 2 þ release (cytosolic-free calcium) and mitochondria Ca 2 þ load, ROS production, pro-caspase-12 level, and caspase3 activity as indicated (n ¼ 3, *P o0.05 versus vector group). WAVE1 regulates Bcl-2 R Kang et al used anti-cancer drugs in clinic leukemia. In contrast, suppression of WAVE1 expression by RNA interference increased the sensitivity of leukemia cells to anti-cancer drugs or ER stress (for example thapsigargin), suggesting an important anti-apoptotic role for WAVE1 in leukemia cells.
Our experimental data suggest that WAVE1 may be involved in the counter-regulation of ROS production and Ca 2 þ homeostasis in leukemia cells. ROS can be induced by many chemotherapeutic agents (such as ADM, AS2O3) and radiation therapy during cancer therapy, 24, 33 and has been proposed as common mediators for apoptosis in leukemia cells. 34 Recent studies have shown that the mode of cell death depends on the severity of the oxidative damage. 33 We found that suppression of WAVE1 expression by RNAi increased ADMand thapsigargin-induced ROS production, and Ca 2 þ released into the cytoplasm from the ER. Alterations in Ca 2 þ homeostasis and accumulation of misfolded proteins in the ER cause ER stress that ultimately leads to apoptosis. 35 ER Ca 2 þ release leads to rapid calcium uptake and accumulation in mitochondria (ER/mitochondria coupling), 36 leading to mitochondrial permeability transition pore opening and cytochrome c release prior onset of apoptosis. 36 Furthermore, WAVE1 confers anti-apoptotic activities potentially through controlling Bcl-2 intracellular localization and post-translational modification, which in turn regulates intracellular ROS levels and Ca 2 þ homeostasis. Bcl-2, an integral membrane protein located on the ER and mitochondria, is an important inhibitor of apoptosis, although its mechanism of localization is not fully understood. 37, 38 Mitochondria bcl-2 prevents the increase in mitochondrial outer membrane permeabilization and protects cells from various death insults partly by regulated ROS. 3, [27] [28] [29] Our experimental data suggest that WAVE1 may function as an anchoring protein for mitochondrial Bcl-2, because (1) WAVE1 is co-immunoprecipitated with Bcl-2 from mitochondrial fraction of leukemia cells; (2) deletion of WAVE1 expression led to a parallel decrease in mit-Bcl-2 and increase in ER-Bcl-2, thus the mitochondrial localization of mature full-length Bcl-2 (Bcl-2-GFP) was impaired in WAVE1-depleted cells; and (3) Bcl-2 did not inhibit ADM-induced cell death in WAVE1-deficient leukemia cells.
In response to diverse stimuli including treatment with chemotherapeutic taxanes, Bcl-2 is phosphorylated on specific residues within an unstructured loop, and is associated with poor survival in leukemia patient. [3] [4] [5] [6] Bcl-2 may be phosphorylated by kinases of the JNK signaling pathway, and involved in the regulation of ER Ca 2 þ homeostasis and cell death during apoptosis and autophagy. 30, 31 Thus, Bcl-2 regulates ER-tomitochondrion communication by Ca 2 þ and thereby triggers mitochondrial dysfunction and cell death. 37 Our experimental data suggest that WAVE1 may be involved in the regulation of Bcl-2 phosphorylation, because depletion of WAVE1 expression led to an increase in thapsigargin-induced phosphorylation WAVE1 regulates Bcl-2 R Kang et al of JNK1/2, and an upstream signaling kinase ASK1. Indeed, the JNK and ASK1 have been reported to be activated by an ER-resident complex following ER stress. 39 Notably, the ability of the GFP tag to dimerize may potentially cause dimerization of GFP-Bcl-2 at the expense of interaction with other natural counterparts (for example Bad or Bcl-XL), which may partly explain why WAVE1 fails to interact with other Bcl-2-binding proteins (for example Bad or Bcl-XL). In addition, other adaptor proteins (such as Pancortin-2) are needed for WAVE1 to interact with Bcl-XL in neuronal cells, because disruption of pancortin-2 expression prevents WAVE1/ Bcl-XL interaction in these cells. 16 We do not know, however, whether such adaptor proteins (for example Pancortin-2) are expressed in human leukemia cells, and whether a potential lack of pancortin-2 expression accounts for the failure of WAVE1 to interact with Bcl-XL in human leukemia cells.
In summary, here we showed that WAVE1 was overexpressed in blood cancer cell lines, and functioned as a negative regulator of apoptosis. Enhanced expression of WAVE1 by gene transfection rendered leukemia cells more resistant to anti-cancer drug-induced apoptosis; whereas suppression of WAVE1 expression by RNA interference restored leukemia cells' sensitivity to anti-drug-induced apoptosis. WAVE1 formed complexes with Bcl-2 in the mitochondria, and regulated Bcl-2 localization and phosphorylation, thereby regulating mitochondrial ROS levels and ER Ca 2 þ homeostasis (Figure 7g ). In light of the therapeutic promise of gene therapy to render tumor cells more susceptible to conventional therapies, 40 our discovery of WAVE1 as a key Bcl-2 regulator in leukemia cells may lead to the development of novel drugs for treatment of human leukemia.
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